Journal ArticleDOI
Characterizing neoantigens for personalized cancer immunotherapy.
Reads0
Chats0
TLDR
The properties of neoantigens that influence their immunogenicity are discussed, along with questions that remain to be addressed in order to improve prediction algorithms.About:
This article is published in Current Opinion in Immunology.The article was published on 2017-06-01. It has received 55 citations till now. The article focuses on the topics: Cancer immunotherapy & Cancer.read more
Citations
More filters
Journal ArticleDOI
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
TL;DR: In this paper, the authors review the tumour-derived factors modulating DC function, and summarize evidence of immune evasion by means of quantitative modulation or qualitative alteration of the antigen repertoire presented on tumours.
Journal ArticleDOI
Noncoding regions are the main source of targetable tumor-specific antigens
Céline M. Laumont,Krystel Vincent,Leslie Hesnard,Éric Audemard,Eric Bonneil,Jean-Philippe Laverdure,Patrick Gendron,Mathieu Courcelles,Marie-Pierre Hardy,Caroline Côté,Chantal Durette,Charles St-Pierre,Mohamed Benhammadi,Joel Lanoix,Suzanne Vobecky,Elie Haddad,Sébastien Lemieux,Pierre Thibault,Claude Perreault +18 more
TL;DR: The authors validated the immunogenicity and efficacy of TSA vaccination for select antigens in mouse models of cancer and demonstrated that the strength of antitumor responses after TSA vaccination was influenced by two parameters that can be estimated in humans and could serve for TSA prioritization in clinical studies.
Journal ArticleDOI
Current Perspectives in Cancer Immunotherapy.
Theodoulakis Christofi,Stavroula Baritaki,Luca Falzone,Massimo Libra,Apostolos Zaravinos,Apostolos Zaravinos +5 more
TL;DR: The current immunotherapeutic approaches against cancer, including immune checkpoint blockade with an emphasis on anti-PD-L1 and anti-CTLA-4 monoclonal antibodies are discussed, as well as on drugs that either have been FDA-approved or are under clinical investigation.
Journal ArticleDOI
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
Yugang Guo,Kewen Lei,Li Tang +2 more
TL;DR: Current delivery approaches, including direct injection, ex vivo-pulsed dendritic cell vaccination, and biomaterial-assisted vaccination for enhancing the efficiency of neoantigen vaccines are discussed and a perspective on future directions is presented.
Journal ArticleDOI
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
Laetitia Nebot-Bral,David Brandao,Loic Verlingue,Etienne Rouleau,Olivier Caron,Emmanuelle Despras,Yolla El-Dakdouki,Stéphane Champiat,Said Aoufouchi,Alexandra Leary,Aurélien Marabelle,David Malka,Nathalie Chaput,Patricia Kannouche,Patricia Kannouche,Patricia Kannouche +15 more
TL;DR: An overview of recent data on hypermutated tumours, including MMRD and POLE-mutated cancers, with a focus on their distinctive clinicopathological and molecular characteristics as well as their immune environment is provided.
References
More filters
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi,Naiyer A. Rizvi,Matthew D. Hellmann,Matthew D. Hellmann,Alexandra Snyder,Alexandra Snyder,Pia Kvistborg,Vladimir Makarov,Jonathan J. Havel,William Lee,Jianda Yuan,Phillip Wong,Teresa S. Ho,Martin L. Miller,Natasha Rekhtman,Andre L. Moreira,Fawzia Ibrahim,Cameron Bruggeman,Billel Gasmi,Roberta Zappasodi,Yuka Maeda,Chris Sander,Edward B. Garon,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok,Ton N. Schumacher,Timothy A. Chan,Timothy A. Chan +28 more
TL;DR: Treatment efficacy was associated with a higher number of mutations in the tumors, and a tumor-specific T cell response paralleled tumor regression in one patient, suggesting that the genomic landscape of lung cancers shapes response to anti–PD-1 therapy.
Journal ArticleDOI
Oncology Meets Immunology: The Cancer-Immunity Cycle
TL;DR: Emerging clinical data suggest that cancer immunotherapy is likely to become a key part of the clinical management of cancer and may be more effective in combination with agents that target other steps of the cycle.
Journal ArticleDOI
Neoantigens in cancer immunotherapy
TL;DR: Observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
Journal ArticleDOI
The future of immune checkpoint therapy
Padmanee Sharma,James P. Allison +1 more
TL;DR: The way forward for this class of novel agents lies in the ability to understand human immune responses in the tumor microenvironment, which will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
Related Papers (5)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott,Zhuting Hu,Derin B. Keskin,Derin B. Keskin,Sachet A. Shukla,Sachet A. Shukla,Jing Sun,David J. Bozym,Wandi Zhang,Adrienne M. Luoma,Anita Giobbie-Hurder,Lauren Peter,Christina Chen,Oriol Olive,Todd A. Carter,Shuqiang Li,David J. Lieb,Thomas Eisenhaure,Evisa Gjini,Jonathan Stevens,William J. Lane,Indu Javeri,Kaliappanadar Nellaiappan,Andres M. Salazar,Heather Daley,Michael S. Seaman,Elizabeth I. Buchbinder,Elizabeth I. Buchbinder,Charles H. Yoon,Maegan Harden,Niall J. Lennon,Stacey Gabriel,Scott J. Rodig,Scott J. Rodig,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Jon C. Aster,Jon C. Aster,Gad Getz,Gad Getz,Kai W. Wucherpfennig,Donna Neuberg,Jerome Ritz,Jerome Ritz,Eric S. Lander,Eric S. Lander,Edward F. Fritsch,Edward F. Fritsch,Nir Hacohen,Nir Hacohen,Catherine J. Wu +51 more
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin,Evelyna Derhovanessian,Matthias Miller,Björn-Philipp Kloke,Petra Simon,Martin Löwer,Valesca Bukur,Arbel D. Tadmor,Ulrich Luxemburger,Barbara Schrörs,Tana Omokoko,Mathias Vormehr,Christian Albrecht,Anna Paruzynski,Andreas Kuhn,Janina Buck,Sandra Heesch,Katharina H Schreeb,Felicitas Müller,Inga Ortseifer,Isabel Vogler,Eva Godehardt,Sebastian Attig,Richard Rae,Andrea Breitkreuz,Claudia Tolliver,Martin Suchan,Goran Martic,Alexander Hohberger,Patrick Sorn,Jan Diekmann,Janko Ciesla,Olga Waksmann,Alexandra-Kemmer Brück,Meike Witt,Martina Zillgen,Andrée Rothermel,Barbara Kasemann,David Langer,Stefanie Bolte,Mustafa Diken,Sebastian Kreiter,Romina Nemecek,Christoffer Gebhardt,Christoffer Gebhardt,Stephan Grabbe,Christoph Höller,Jochen Utikal,Jochen Utikal,Christoph Huber,Carmen Loquai,Özlem Türeci +51 more
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin,Xiuli Zhang,Heiko Schuster,Etienne Caron,Jeffrey P. Ward,Takuro Noguchi,Yulia Ivanova,Jasreet Hundal,Cora D. Arthur,Willem Jan Krebber,Gwenn E. Mulder,Mireille Toebes,Matthew D. Vesely,Samuel S. K. Lam,Alan J. Korman,James P. Allison,Gordon J. Freeman,Arlene H. Sharpe,Erika L. Pearce,Ton N. Schumacher,Ruedi Aebersold,Hans-Georg Rammensee,Cornelis J. M. Melief,Elaine R. Mardis,William E. Gillanders,Maxim N. Artyomov,Robert D. Schreiber +26 more